Aclaris Therapeutics, Inc.
ACRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$132,065 | -$88,481 | -$86,908 | -$90,865 |
| Dep. & Amort. | $807 | $863 | $797 | $923 |
| Deferred Tax | $0 | -$367 | $0 | $752 |
| Stock-Based Comp. | $10,856 | $20,542 | $15,039 | $14,060 |
| Change in WC | $10,922 | $9,389 | -$1,195 | -$1,343 |
| Other Non-Cash | $89,405 | -$20,271 | $4,700 | $24,339 |
| Operating Cash Flow | -$20,075 | -$78,325 | -$67,567 | -$52,134 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$121 | -$1,309 | -$605 | -$308 |
| Net Acquisitions | $0 | $0 | -$13,233 | $167,324 |
| Inv. Purchases | -$119,982 | -$135,675 | -$164,753 | -$235,153 |
| Inv. Sales/Matur. | $86,144 | $183,204 | $177,986 | $67,829 |
| Other Inv. Act. | -$35,810 | $0 | $13,233 | -$167,324 |
| Investing Cash Flow | -$69,769 | $46,220 | $12,628 | -$167,632 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | -$11,483 |
| Stock Issued | $74,913 | $26,714 | $72,744 | $238,200 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$377 | -$8 | $123 | -$1,665 |
| Financing Cash Flow | $74,536 | $26,706 | $72,867 | $225,052 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$15,308 | -$5,399 | $17,928 | $5,286 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $39,878 | $45,277 | $27,349 | $22,063 |
| End Cash | $24,570 | $39,878 | $45,277 | $27,349 |
| Free Cash Flow | -$20,196 | -$79,634 | -$68,172 | -$52,442 |